Torii Pharmaceutical
4551.TTSE PRIME
Financials · Standalone
| Fiscal year ended | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥60.4bn | ¥54.6bn | ¥48.9bn | ¥47.0bn | ¥41.7bn | ¥43.0bn |
| Operating income | ¥6.8bn | ¥5.0bn | ¥5.5bn | ¥4.7bn | — | — |
| Ordinary income | ¥6.9bn | ¥5.3bn | ¥5.5bn | ¥4.8bn | ¥5.0bn | ¥1.7bn |
| Total assets | ¥140.7bn | ¥133.4bn | ¥133.7bn | ¥130.8bn | ¥126.0bn | ¥139.9bn |
| Net assets / equity | ¥121.5bn | ¥120.1bn | ¥119.2bn | ¥117.0bn | ¥115.1bn | ¥113.1bn |
| Operating cash flow | ¥3.6bn | −¥3.1bn | ¥2.4bn | −¥156m | −¥3.4bn | ¥42.5bn |
| EPS (basic) | ¥179.38 | ¥146.6 | ¥140.39 | ¥120.13 | ¥124.47 | ¥974.98 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 11
| Period | Form | Figures |
|---|---|---|
| 2025-01-01 → 2025-06-30 | Half-year | 68 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 119 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 69 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 43 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 119 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 47 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 71 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 43 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 119 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 47 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 71 figures · EDINET |
22 more reports are still being processed.